XML 24 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statements [line items]            
Sales $ 1,397,443 $ 73,096 $ 2,619,682 $ 41,431 $ 2,062
Cost of sales 570,275 12,870 566,252 43,022 1,809
Gross Profit before gain on change in fair value of biological assets and inventory 827,168 60,226 2,053,430 (1,591) 253
Gain on change in fair value of biological assets and inventory 108,239 33,078 1,216,129    
Gross Profit (Loss) 935,407 93,304 3,269,559 (1,591)    
Operating expenses            
Depreciation and amortization 2,150,045 1,511,138 3,598,323 478    
Consulting and professional fees 2,205,504 2,366,997 7,759,824 1,212,422    
Personnel expenses 1,442,231 3,782,727 6,593,527 1,184,734    
Travel expenses       65,667 50,636 56,851
Share-based payment expenses to social development trust 2,174,908 2,124,615    
General and administrative expenses 958,814 1,175,647 3,369,659 170,926    
License fees       5,073 1,491
Total operating expenses 6,756,594 11,011,417 23,445,948 25,685,620    
Operating loss (5,821,187) (10,918,113) (20,176,389) (2,570,151)    
Other income:            
Finance income 20 747 886 90    
Finance expense (224,458) (36,606) (115,324) (10,509)    
Foreign exchange gain (loss), net 152,775 (180,990) (256,431) 106,813    
Gain on bargain purchase 12,760,356 12,760,356    
Gain on debt settlement 10,422 67,075    
Other income 4,082 207 659 54 108
Change in fair value of financial assets measured at FVTPL 464 (472,311) (516,281)    
Total other income (56,695) 12,071,403 11,940,940 96,448    
Net income (loss) from continuing operations (5,877,882) 1,153,290 (8,235,449) (2,473,703)    
Loss from discontinued operations (3,747,034) (3,422,225) (5,657,494)    
Net loss (5,877,882) (2,593,744) (11,657,674) (8,131,197) (2,300,571) (1,394,641)
Translation adjustment (126,995) (1,019,498) (1,395,508) 110,042 150,626 (42,566)
Comprehensive loss $ (6,004,877) $ (3,613,242) $ (13,053,182) $ (8,021,155) $ (2,149,945) $ (1,437,207)
Earnings (loss) per share from continuing operations – basic (in Dollars per share) $ (1.46) $ 0.43 $ (0.28) $ (0.15)    
Loss per share – basic (in Dollars per share) $ (1.46) $ (0.97) $ (0.39) $ (0.5) $ (0.18) $ (0.11)
Weighted average common shares outstanding (in Shares) 4,029,293 2,683,544 29,930,094 16,223,996 13,129,212 13,129,212
Previously Stated            
Statements [line items]            
Gain on change in fair value of biological assets and inventory       $ (713,135) $ (58,429)
Gross Profit (Loss)       (714,726) (58,176)
Operating expenses            
Depreciation and amortization       309,022 248,743 198,824
Consulting and professional fees       1,855,419 702,016 365,641
Personnel expenses       2,379,649 374,900 100,256
General and administrative expenses       1,504,172 229,743 179,663
Total operating expenses       6,119,002 1,607,529 901,235
Operating loss       (6,833,728) (1,665,705) (901,235)
Other income:            
Finance income       26,749 10,188 401
Finance expense       (1,092,881) (645,162) (493,807)
Foreign exchange gain (loss), net       (231,391)
Total other income       (1,297,469) $ (634,866) $ (493,406)
Net loss $ (5,877,882) $ (2,593,744)   (8,131,197)    
Translation adjustment $ (126,995) $ (1,019,498)   $ 110,042